0001213900-21-059456.txt : 20211115 0001213900-21-059456.hdr.sgml : 20211115 20211115164634 ACCESSION NUMBER: 0001213900-21-059456 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 EFFECTIVENESS DATE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Raphael Pharmaceutical Inc. CENTRAL INDEX KEY: 0001415397 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 260204284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53002 FILM NUMBER: 211411799 BUSINESS ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: 702-442-1166 MAIL ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: Easy Energy Inc DATE OF NAME CHANGE: 20071017 NT 10-Q 1 ea150725-nt10q_raphaelphar.htm NOTIFICATION OF LATE FILING

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

  

(Check one):  ☐ Form 10-K ☐  Form 20-F ☐  Form 11-K  ☑  Form 10-Q ☐  Form 10-D  ☐  Form N-CEN  ☐  Form N-CSR

 

For Period Ended: September 30, 2021

   

  ☐ Transition Report on Form 10-K

 

  ☐ Transition Report on Form 20-F

   

  ☐ Transition Report on Form 11-K

   

  ☐ Transition Report on Form 10-Q

   

For the Transition Period Ended:

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION 

 

Raphael Pharmaceutical Inc.

Full Name of Registrant

 

Easy Energy, Inc.

Former Name if Applicable

 

4 Lui Paster

Address of Principal Executive Office (Street and Number)

 

Tel Aviv-Jaffa, Israel 6803605

City, State and Zip Code

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☐ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
☑ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed date; and
     
☐ (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

 

 

PART III — NARRATIVE 

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

 

The Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2021 cannot be filed within the prescribed time period because the Company requires additional time to prepare and get the documents edgarized to ensure adequate submission of the Form 10-Q. The Company’s Quarterly Report on Form 10-Q will be filed on or before the 5th calendar day following the prescribed due date.

 

PART IV — OTHER INFORMATION

 

  (1) Name and telephone number of person to contact in regard to this notification

 

  Shlomo Pilo   +972   52-7755072
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
  Yes ☑     No ☐
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
  Yes  ☐    No ☑
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
   

 

2

 

 

  Raphael Pharmaceutical Inc.  
  (Name of Registrant as Specified in Charter)  

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 15, 2021   By: /s/ Shlomo Pilo
      Name: Shlomo Pilo
      (Title): Chief Executive Officer and Director
     

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

 

ATTENTION 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)

 

 

 

3